UBS analyst Carter Gould lowered his price target on Regeneron (REGN) to $500 from $535 citing increased Dupixent competition after Amgen (AMGN) and AstraZeneca (AZN) reported data on their own asthma drug earlier this month and AbbVie (ABBV) reported results in an atopic dermatitis study. While he noted that definitive 12-month phase 3 data from these competitors is likely more than 20 months away, he also lowered his Dupixent peak sales estimate to $4.8B from $6.5B. He keeps a Buy rating on Regeneron shares, as he believes pipeline products including nesvacumab and REGN2810 offer a path to longer-term upside.

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $2.20... Chevron (CVX), consensus $2.87... AbbVie (ABBV), consensus $2.23... HCA Healthcare (HCA), consensus $5.01... Colgate-Palmolive (CL), consensus 81c... Charter (CHTR), consensus $7.92... AutoNation (AN), consensus $4.27.

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.

Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.